Seattle Genetics, Inc. (NASDAQ:SGEN)

CAPS Rating: 3 out of 5

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.

Recs

0
Player Avatar Kdixon7959 (< 20) Submitted: 8/26/2011 10:49:47 PM : Outperform Start Price: $15.95 SGEN Score: +23.11

Great pipeline of products

Report this Post Reply

Featured Broker Partners


Advertisement